thumbnail image
  • Home
  • About Us
  • Portfolio
  • News
  • Contact Us
    • POWER THE COURSE OF FIGHTING DISEASES AND SAVING LIVES

      Domain expertise, global resource, long-term capital

    • PORTFOLIO NEWS

      ProfoundBio Announces Completion of $70 Million Series A+ Financing to Advance Antibody-Drug Conjugate (ADC) Programs into the Clinic
      2022年6月2日
      - Advance PRO1184 and PRO1160 into clinical trials - Accelerate multiple programs into...
      Rona Therapeutics Announces Completion of $33 Million Series A Financing to Advance Global Discovery and Development of RNA Therapeutics
      2022年4月7日
        - Funding from long-term investors to build leading delivery platform and scalable drug...
      CARVYKTI™ (ciltacabtagene autoleucel), BCMA-Directed CAR-T Therapy, Receives U.S. FDA Approval for the Treatment of Adult Patients With Relapsed or Refractory Multiple Myeloma
      2022年3月1日
      CARVYKTI™ marks the first product approved by a health authority for Legend BiotechApproval is...
      Abbisko Therapeutics Announces Worldwide Collaboration with Lilly to Discover and Develop Novel Molecules
      2022年1月19日
      Collaboration Combines Abbisko Therapeutics' Proprietary Drug Discovery Platform with Lilly's...
      Sperogenix and Santhera Enters into Exclusive License Agreement for Vamorolone in Rare Diseases in the Greater China Region
      2022年1月5日
      Sperogenix will receive exclusive rights for development and commercialization of vamorolone for...
      BioMarin and Skyline Therapeutics Announce Strategic Collaboration to Develop Novel Gene Therapies for Cardiovascular Diseases
      2021年12月17日
      SAN RAFAEL, Calif. and SHANGHAI, Dec. 16, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. ...
      Regor and Lilly Enter into Strategic Collaboration to Discover and Develop Novel Therapies for Metabolic Disorders
      2021年12月10日
      INDIANAPOLIS and SHANGHAI, Dec. 10, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and...
      Singleron Completes Series B Financing
      2021年11月9日
      2021/11/09 -- Singleron Biotechnologies, an innovative biotech company dedicated to applying...
      More Posts

    Company

     

    Shanghai

    Room 2909-14, 168 Hubin Road, Huangpu District, Shanghai, China.

     

     

    Hong Kong

    Room 606-7, St. George's Building, 2 Ice House Street, Central, Hong Kong

     

     

    US

    2735 Sand Hill Road, Suite 210

    Menlo Park, CA 94025

    copyright © 2018 Lilly Asia Ventures all rights reserved.

    沪公网安备 31010102005458号
    |
    沪ICP备12003647号-1
      All Posts
      ×
      LillyAsiaVentures
      Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm headquartered in China, with offices in Shanghai, Hong Kong, and Palo Alto.
      https://user-assets.sxlcdn.com/images/315509/FnksTvTDur7jpExbqYminmtjWgoM.png?imageMogr2/strip/auto-orient/thumbnail/1200x630>/format/png
      Cookie Use
      We use cookies to ensure a smooth browsing experience. By continuing we assume you accept the use of cookies.
      Learn More